172 related articles for article (PubMed ID: 37728376)
1. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
Cilloniz C; Torres A
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):569-576. PubMed ID: 37728376
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).
Carvalhaes CG; Huband MD; Reinhart HH; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617092
[TBL] [Abstract][Full Text] [Related]
4. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
Villano S; Steenbergen J; Loh E
Future Microbiol; 2016 Oct; 11():1421-1434. PubMed ID: 27539442
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
Macone AB; Caruso BK; Leahy RG; Donatelli J; Weir S; Draper MP; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(2):1127-35. PubMed ID: 24295985
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018.
Dong D; Zheng Y; Chen Q; Guo Y; Yang Y; Wu S; Zhu D; Deng D; Bradford PA; Reinhart H; Hu F
Eur J Clin Microbiol Infect Dis; 2020 Aug; 39(8):1559-1572. PubMed ID: 32356026
[TBL] [Abstract][Full Text] [Related]
8. Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
[TBL] [Abstract][Full Text] [Related]
9. Microbiology and Preclinical Review of Omadacycline.
Karlowsky JA; Steenbergen J; Zhanel GG
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S6-S15. PubMed ID: 31367743
[TBL] [Abstract][Full Text] [Related]
10. Evaluating omadacycline dosing regimens against drug-resistant pathogens including
Wei XC; Zhao MF; Xiao X
J Chemother; 2024 Apr; ():1-8. PubMed ID: 38591989
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.
Pfaller MA; Huband MD; Shortridge D; Flamm RK
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071045
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
[TBL] [Abstract][Full Text] [Related]
13. Omadacycline in treating community-based infections: a review and expert perspective.
Sakoulas G; Nowak M; Geriak M
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):255-265. PubMed ID: 36718489
[TBL] [Abstract][Full Text] [Related]
14. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.
Pfaller MA; Huband MD; Rhomberg PR; Flamm RK
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223386
[TBL] [Abstract][Full Text] [Related]
16. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
[TBL] [Abstract][Full Text] [Related]
17. Omadacycline: A Modernized Tetracycline.
Gallagher JC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S1-S5. PubMed ID: 31367739
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.
Draper MP; Weir S; Macone A; Donatelli J; Trieber CA; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(3):1279-83. PubMed ID: 24041885
[TBL] [Abstract][Full Text] [Related]
19. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
20.
Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
